Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced mÃ¼llerian malignancies: the modified triple doublet regimen.
Gynecol. Oncol., Nov;103(2):575-80 (2006)
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
J. Clin. Oncol., Dec;26(35):5761-6 (2008)
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed MÃ¼llerian tumors.
Gynecol. Oncol., Feb;112(2):394-9 (2009)
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
J. Allergy Clin. Immunol., Jun;123(6):1262-7.e1 (2009)
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
J. Clin. Oncol., Jan;28(1):154-9 (2010)
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
Gynecol. Oncol., Oct;103(1):160-4 (2006)
Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone.
Gynecol. Oncol., Oct;127(1):161-7 (2012)
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
Br. J. Cancer., Dec;97(12):1618-24 (2007)
Phase II trial of GM-CSF in women with asymptomatic recurrent mÃ¼llerian tumors.
Gynecol. Oncol., Feb;116(2):168-72 (2010)
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
Int. J. Clin. Oncol., Aug;15(4):390-8 (2010)
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent MÃ¼llerian Carcinoma.
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
Gynecol. Oncol., Oct;127(1):141-6 (2012)
Detection of Staphylococcus aureus in peripheral blood stem cell cultures after sterilization of standard blood cultures.
J Clin Apher., 18(1):37-9 (2003)
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Gynecol. Oncol., Dec;95(3):624-31 (2004)